渤健 2025 JP Morgan Presentation_vFINAL 1.14.25.pdf

《渤健 2025 JP Morgan Presentation_vFINAL 1.14.25.pdf》由会员分享，可在线阅读，更多相关《渤健 2025 JP Morgan Presentation_vFINAL 1.14.25.pdf（25页珍藏版）》请在三个皮匠报告上搜索。

1、2Forward-looking statementsThis presentation and the discussions during this webcast contain forward-looking statements,relating to:our strategy and plans;potential of,and expectations for,our commercial business and pipeline programs;capital allocation and investment strategy;clinical development p

2、rograms,clinical trials,and data readouts and presentations;regulatory discussions,submissions,filings,and approvals;the potential benefits,safety,and efficacy of our and our collaboration partners products and investigational therapies;the anticipated benefits and potential of investments and acqui

3、sitions,optimization of the cost structure including our“Fit for Growth”program,actions to improve risk profile and productivity of R&D pipeline,collaborations,and business development activities;our future financial and operating results and 2024 financial guidance.These forward-looking statements

4、may be accompanied by such words as“aim,”“anticipate,”“believe,”“could,”“estimate,”“expect,”“forecast,”“goal,”“intend,”“may,”“plan,”“potential,”“possible,”“prospect,”“will,”“would,”and other words and terms of similar meaning.Drug development and commercialization involve a high degree of risk,and o

5、nly a small number of research and development programs result in commercialization of a product.Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.You should not place undue r

6、eliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements,including:our dependence on sales from our products;uncertainty of long-term success in developing,licensing,or acquiring other pr